Literature DB >> 11959611

Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.

P M Loiseau1, L Imbertie, C Bories, D Betbeder, I De Miguel.   

Abstract

A new delivery system, Ionic Amphiphilic Biovector (ABV), comprised of anionic lipids (dipalmitoyl phosphatidyl glycerol) included in a cationic cross-linked polysaccharide matrix was used as a reservoir for amphotericin B (AmB). Two ABV formulations exhibited an in vitro and in vivo efficacy similar to commercial AmBisome against Leishmania donovani-infected mice. The higher stability of these ABV formulations indicates their potential for further development and applications.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11959611      PMCID： PMC127191          DOI： 10.1128/AAC.46.5.1597-1601.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  Liposomal amphotericin B in drug-resistant visceral leishmaniasis.

Authors:  R N Davidson; S L Croft; A Scott; M Maini; A H Moody; A D Bryceson
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

2.  In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188.

Authors:  S Espuelas; P Legrand; P M Loiseau; C Bories; G Barratt; J M Irache
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Mechanism of amphotericin B resistance in Leishmania donovani promastigotes.

Authors:  N Mbongo; P M Loiseau; M A Billion; M Robert-Gero
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191
  3 in total
  7 in total

1.  Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.

Authors:  Hector Nakayama; Philippe M Loiseau; Christian Bories; Susana Torres de Ortiz; Alicia Schinini; Elsa Serna; Antonieta Rojas de Arias; Mohamed A Fakhfakh; Xavier Franck; Bruno Figadère; Reynald Hocquemiller; Alain Fournet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.

Authors:  Hamdan I Al-Mohammed; Michael L Chance; Paul A Bates
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Isolation, phylogenetic analysis and anti-infective activity screening of marine sponge-associated actinomycetes.

Authors:  Usama Ramadan Abdelmohsen; Sheila M Pimentel-Elardo; Amro Hanora; Mona Radwan; Soad H Abou-El-Ela; Safwat Ahmed; Ute Hentschel
Journal:  Mar Drugs       Date:  2010-02-26       Impact factor: 5.118

4.  Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.

Authors:  Malika Larabi; Vanessa Yardley; Philippe M Loiseau; Martine Appel; Philippe Legrand; Annette Gulik; Christian Bories; Simon L Croft; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

5.  Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers.

Authors:  Archibald Paillard; Catherine Passirani; Patrick Saulnier; Maya Kroubi; Emmanuel Garcion; Jean-Pierre Benoît; Didier Betbeder
Journal:  Pharm Res       Date:  2009-10-23       Impact factor: 4.200

Review 6.  Nanostructured delivery systems with improved leishmanicidal activity: a critical review.

Authors:  Natascia Bruni; Barbara Stella; Leonardo Giraudo; Carlo Della Pepa; Daniela Gastaldi; Franco Dosio
Journal:  Int J Nanomedicine       Date:  2017-07-26

7.  Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity.

Authors:  Pushkar Shivam; Saptarshi Mandal; Prakash Kumar; Pragya Prasanna; Saurabh Kumar; Surendra Rajit Prasad; Ashish Kumar; Prolay Das; Vahab Ali; Shubhankar Kumar Singh; Debabrata Mandal
Journal:  Int J Nanomedicine       Date:  2019-08-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.